Since 2014
Treatment cost of metastatic colon cancer in Turkey
Farmeconomia
View Archive Info| Field | Value | |
| Title |
Treatment cost of metastatic colon cancer in Turkey
|
|
| Creator |
Kockaya, Guvenc
Polat, Mine Wertheimer, Albert Ozet, Ahmet Malhan, Simten Vural, İsmail Mert Akbulat, Akif Artıran, Guven Gursoz, Hakkı Kerman, Saim |
|
| Subject |
pharmacoeconomics
Oncology; Colon cancer; Cost-effectiveness |
|
| Description |
OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% of whom are diagnosed to have developed colon cancer. Metastases will occur in up to 50% of the patients who are newly diagnosed. Survival appears to be further prolonged to more than 20 months with new pharmaceuticals; however, these new pharmaceuticals increase the total cost of care. The aim of this study is to estimate the cost implications of new colon cancer treatment options for Turkey.METHODS: Gazi University Hospital treatment protocols for colon cancer treatment were used. Cost of FUFA (5 FU/LV), FOLFIRI, FOLFOX, bevacizumab/FUFA, bevacizumab/FOLFIRI, bevacizumab/FOLFOX, irinotecan and irinotecan/cetixumab protocols were calculated. The cost of combination of protocols were calculated depending on a Markov analysis. The exchange rate was US$ 1 for TL 1.5.RESULTS: Depending on the life expectancy the lowest total cost was established by FUVA (US$ 5,359). It was followed by FOLFIRI then FOLFOX and FOLFOX, US$ 14,144 and US$ 16,553, respectively. The lowest cost for each week of life expectancy was established by FUVA with US$ 98.CONCLUSIONS: Only FUFA, FOLFIRI followed by FOLFIX, FOLFIRI/bevacizumab then FOLFOX then cetuximab, FOLFOX/bevacizumab then irinotecan then cetuximab/irinotecan and FOLFIRI/bevacizumab then FOLFOX then cetuximab/irinotecan were under the cost effectiveness curve. In addition no treatments ICER was under the WHO`s threshold for Turkey, except FOLFIRI then FOLFOX compared with FUVA.
|
|
| Publisher |
SEEd
|
|
| Contributor |
The authors have no financial competing interest to declare
|
|
| Date |
2013-01-30
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
text/html
application/pdf |
|
| Identifier |
http://journals.edizioniseed.it/index.php/FE/article/view/472
10.7175/fe.v14i1.472 |
|
| Source |
Farmeconomia. Health economics and therapeutic pathways; Vol 14, No 1 (2013); 19-25
2240-256X 1721-6915 |
|
| Language |
eng
|
|
| Relation |
http://journals.edizioniseed.it/index.php/FE/article/view/472/739
http://journals.edizioniseed.it/index.php/FE/article/view/472/740 http://journals.edizioniseed.it/index.php/FE/article/downloadSuppFile/472/38 |
|
| Coverage |
—
— — |
|